.After a few years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma fold, occupying the leading science area at Sanofi.Quigley will begin Sept. 30 as the French Big Pharma’s primary medical officer and worldwide head of study, Sanofi informed Fierce Biotech in an emailed declaration.Quigley is actually switching out Frank Nestle, M.D., who left Sanofi this spring among an international overhaul of the provider’s R&D device. Nestle, that invested eight years with the pharma, leapt over to Deerfield Control, where he presently works as a partner on the therapies team and also chief executive officer of the agency’s healing discovery as well as advancement procedures.
Quigley is going to participate in Sanofi coming from a San Francisco-based biotech that remains in secrecy, according to his LinkedIn profile. He’s presently noted as the firm’s founder, president and also CEO.Because August 2021, Quigley has acted as an endeavor companion at SV Wellness Investors, a health care fund manager with current expenditures in biotechs such as BioAge, Cerevance, Dualitas Therapies as well as Nimbus Therapeutics, and many more. Quigley previously held the top location at Dualitas, a biotech that continues to be in secrecy, depending on to STAT.The future Sanofi forerunner also formerly helmed Therini Biography, an immunotherapy biotech operating to establish procedures for neurodegenerative illness steered by vascular disorder.Before devoting the final few years in biotech, Quigley has an even longer track record in Major Pharma, most lately serving as Gilead’s senior vice president of analysis the field of biology till the summer months of 2021.
Just before that, he clocked in much more than four years across various leadership parts at Bristol Myers Squibb and worked as a scientific director at Johnson & Johnson’s Janssen arm before that.Sanofi pointed out Quigley’s objective in his brand-new duty would be actually to “maximize our likelihood of effectiveness by means of optimum cooperations all over our institution and past, bringing best-in-class technology as well as creating and sourcing new industry-leading talent along with a commitment to diversity,” depending on to an internal memorandum obtained by STAT.